164 related articles for article (PubMed ID: 21633642)
1. p53 antibodies, metallothioneins, and oxidative stress markers in chronic ulcerative colitis with dysplasia.
Hamouda HE; Zakaria SS; Ismail SA; Khedr MA; Mayah WW
World J Gastroenterol; 2011 May; 17(19):2417-23. PubMed ID: 21633642
[TBL] [Abstract][Full Text] [Related]
2. Human protozoa infection and dysplasia in ulcerative colitis: a neglected aspect in a prominent disease.
Abdel Hamed EF; Mostafa NE; Farag SM; Ibrahim MN; Ibrahim BH; Rashed HE; Radwan M; Mohamed SY; El Hendawy R; Fawzy EM
Parasitol Res; 2023 Nov; 122(11):2709-2718. PubMed ID: 37710023
[TBL] [Abstract][Full Text] [Related]
3. Serum p53 antibodies in patients affected with ulcerative colitis.
Cioffi M; Riegler G; Vietri MT; Pilla P; Caserta L; Carratù R; Sica V; Molinari AM
Inflamm Bowel Dis; 2004 Sep; 10(5):606-11. PubMed ID: 15472522
[TBL] [Abstract][Full Text] [Related]
4. Metallothionein: early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma.
Bruewer M; Schmid KW; Krieglstein CF; Senninger N; Schuermann G
World J Surg; 2002 Jun; 26(6):726-31. PubMed ID: 12053227
[TBL] [Abstract][Full Text] [Related]
5. Serum p53 antibody detection in patients with impaired lung function.
Mattioni M; Chinzari P; Soddu S; Strigari L; Cilenti V; Mastropasqua E
BMC Cancer; 2013 Feb; 13():62. PubMed ID: 23384026
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis.
Yoshizawa S; Matsuoka K; Inoue N; Takaishi H; Ogata H; Iwao Y; Mukai M; Fujita T; Kawakami Y; Hibi T
Inflamm Bowel Dis; 2007 Jul; 13(7):865-73. PubMed ID: 17285596
[TBL] [Abstract][Full Text] [Related]
7. Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis.
van Schaik FD; Oldenburg B; Offerhaus GJ; Schipper ME; Vleggaar FP; Siersema PD; van Oijen MG; Ten Kate FJ
Inflamm Bowel Dis; 2012 Mar; 18(3):480-8. PubMed ID: 21509910
[TBL] [Abstract][Full Text] [Related]
8. Increased plasma levels of advanced oxidation protein products (AOPP) as a marker for oxidative stress in patients with active ulcerative colitis.
Alagozlu H; Gorgul A; Bilgihan A; Tuncer C; Unal S
Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):80-5. PubMed ID: 22572519
[TBL] [Abstract][Full Text] [Related]
9. Up-regulation of mitochondrial chaperone TRAP1 in ulcerative colitis associated colorectal cancer.
Chen R; Pan S; Lai K; Lai LA; Crispin DA; Bronner MP; Brentnall TA
World J Gastroenterol; 2014 Dec; 20(45):17037-48. PubMed ID: 25493016
[TBL] [Abstract][Full Text] [Related]
10. Relationship of cytokines, oxidative stress and GI motility with bacterial overgrowth in ulcerative colitis patients.
Rana SV; Sharma S; Kaur J; Prasad KK; Sinha SK; Kochhar R; Malik A; Morya RK
J Crohns Colitis; 2014 Aug; 8(8):859-65. PubMed ID: 24456736
[TBL] [Abstract][Full Text] [Related]
11. Enhanced formation of advanced oxidation protein products in IBD.
Krzystek-Korpacka M; Neubauer K; Berdowska I; Boehm D; Zielinski B; Petryszyn P; Terlecki G; Paradowski L; Gamian A
Inflamm Bowel Dis; 2008 Jun; 14(6):794-802. PubMed ID: 18213700
[TBL] [Abstract][Full Text] [Related]
12. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance.
Navaneethan U; Jegadeesan R; Gutierrez NG; Venkatesh PG; Hammel JP; Shen B; Kiran RP
J Crohns Colitis; 2013 Dec; 7(12):e684-91. PubMed ID: 23916526
[TBL] [Abstract][Full Text] [Related]
13. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis.
Venkatesh PG; Jegadeesan R; Gutierrez NG; Sanaka MR; Navaneethan U
J Crohns Colitis; 2013 Dec; 7(12):968-73. PubMed ID: 23433613
[TBL] [Abstract][Full Text] [Related]
14. Mucosal immune environment in colonic carcinogenesis: CD80 expression is associated to oxidative DNA damage and TLR4-NFκB signalling.
Scarpa M; Cardin R; Bortolami M; Kotsafti A; Scarpa MC; Pozza A; Maran G; Picciocchi M; Ruffolo C; D'Incà R; Sturniolo GC; Castagliuolo I; Castoro C; Angriman I
Eur J Cancer; 2013 Jan; 49(1):254-63. PubMed ID: 22704122
[TBL] [Abstract][Full Text] [Related]
15. p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma.
Sato A; MacHinami R
Pathol Int; 1999 Oct; 49(10):858-68. PubMed ID: 10571818
[TBL] [Abstract][Full Text] [Related]
16. Expression of ATF6 as a marker of pre-cancerous atypical change in ulcerative colitis-associated colorectal cancer: a potential role in the management of dysplasia.
Hanaoka M; Ishikawa T; Ishiguro M; Tokura M; Yamauchi S; Kikuchi A; Uetake H; Yasuno M; Kawano T
J Gastroenterol; 2018 May; 53(5):631-641. PubMed ID: 28884228
[TBL] [Abstract][Full Text] [Related]
17. Is ischemia modified albumin a disease activity marker for inflammatory bowel diseases?
Kaplan M; Yuksel M; Ates I; Kilic ZM; Kilic H; Kuzu UB; Kayacetin E
J Gastroenterol Hepatol; 2016 Jun; 31(6):1120-5. PubMed ID: 26642816
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of serum p53 antibodies in patients with upper urinary tract tumors.
Watanabe J; Nishiyama H; Kawanishi H; Ito M; Kamoto T; Ogawa O
J Urol; 2005 Jul; 174(1):73-5. PubMed ID: 15947581
[TBL] [Abstract][Full Text] [Related]
19. Assessment of dysplasia, mucosal mucins, p53 protein expression, and DNA content in ulcerative colitis patients with colectomy and ileorectal anastomosis.
Navratil E; Stettler C; Paul G; Vilotte J; Vissuzaine C; Mignon M; Potet F
Scand J Gastroenterol; 1995 Apr; 30(4):361-6. PubMed ID: 7610353
[TBL] [Abstract][Full Text] [Related]
20. Paraoxonase-1 and arylesterase levels in patients with ulcerative colitis.
Sahin M; Bobusoglu O; Yetim A; Ates F
Arab J Gastroenterol; 2019 Mar; 20(1):14-18. PubMed ID: 30745012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
